Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02694497
Other study ID # FemCure
Secondary ID
Status Completed
Phase
First received February 15, 2016
Last updated April 25, 2018
Start date April 2016
Est. completion date December 31, 2017

Study information

Verified date August 2017
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Multicenter prospective cohort study in Chlamydia trachomatis positive women after regular treatment to understand the transmission of anorectal CT infections.


Description:

Rationale:

Current national and international strategies for the control of Chlamydia trachomatis (CT) critically fail to obtain a reduction in transmission. In women, anorectal infections are about as common as genital CT. Yet anorectal CT remain untested as sexually transmitted infection (STI) clinics, general practitioners, hospital and population testing initiatives largely focus on genital CT. Part of untested anorectal CT is incidentally treated with the treatments applied for genital CT, as in women anorectal CT is often concurrent with genital CT. Yet, it is unknown whether transmission of anorectal CT can still occur after currently recommended treatment. Anorectal and genital CT were observed quite often after regular treatment (up to 40% detection by nucleic acid amplification tests-NAAT). Proposed reasons for such detection include a new (re-)infection from a partner or self-infection from another anatomic, e.g. anorectal, site. Anorectal infections are a potential reservoir for ongoing transmission of genital and anorectal CT in the population, between partners and between anatomic sites of an individual. Yet, neither the transmission potential nor the transmission impact of anorectal infections has been reported. The scientific evidence for the optimal control strategy for anorectal CT and thereby CT in its totality, is lacking.

Objective:

To understand the transmission of anorectal CT infections in women, i.e. from their male sexual partner(s) and from and to the genital region of the same woman, in women who receive routine care, in order to inform guidelines to optimize CT control.

Study population:

Participants are recruited from 3 large Dutch STI clinics, in South Limburg, Amsterdam and Rotterdam. Eligible participants are likely to reflect the STI clinic population, in terms of age, ethnicity and level of education. Participants include genital and/or anorectal CT positive women (n=400).

Study design:

A multicentre prospective cohort study is set up with biological and behavioural measurements after routine treatment of CT. During 3 months, the participants will be studied using a self-administered anorectal and vaginal swab that is self-collected pre-treatment (T0), and at the end of weeks 1, 2, 4, 6, 8, 10, and 12. Samples are tested using NAAT for presence of CT-DNA (detection), concentration (load), viability (weeks 4,8, and 12), and CT type (multilocus sequence typing-MLST) to confirm re-infection. To validate sexual exposure, chromosomal Y DNA (as a marker for semen exposure) in genital and anorectal samples is applied. At each sampling time, online self-administered questionnaires on behaviour (e.g. anorectal exposure) and symptoms will be completed.

Outcomes:

The outcome is detection of anorectal and genital CT at any of the time -points.

Primary outcome is incident detection by NAAT, and secondary outcomes include detection of viable CT and CT-DNA concentration.

Statistical analyses:

In statistical analyses, using logistic regression models, the impact of two key factors will be assessed (i.e. sexual exposure and alternate anatomic site of infection) on detection of anorectal and genital CT. In sub-analyses, the role of treatment-type is evaluated.

Expected results:

This project will provide scientific insight in the role of anorectal CT in maintaining the CT burden, and it will provide practical recommendations (STI guidelines) to reduce avoidable transmission. Implications will be to improve care strategies for (re-)testing and partner management that currently largely neglect anorectal CT, benefitting the individual (better fitting care) and public health (reducing burden) and eventually cost-effectiveness of care.


Recruitment information / eligibility

Status Completed
Enrollment 560
Est. completion date December 31, 2017
Est. primary completion date December 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chlamydia trachomatis test positive (genital and or anorectal)

Exclusion Criteria:

- (reported) co-infection with gonorrhoea

- (reported) co-infection with HIV

- (reported) co-infection with syphilis

- (reported) pregnant

- (reported) anti-Chlamydial antibiotic use (period screening-treatment)

Study Design


Intervention

Other:
Chlamydia care as usual


Locations

Country Name City State
Netherlands Public Health Service South Limburg Geleen South Limburg

Sponsors (7)

Lead Sponsor Collaborator
Maastricht University Medical Center National Institute for Public Health and the Environment (RIVM), Public Health Service of Amsterdam, Public Health Service Rotterdam, Public Health Service South Limburg, STIAIDSNetherlands, ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Dukers-Muijrers NH, Wolffs PF, Eppings L, Götz HM, Bruisten SM, Schim van der Loeff MF, Janssen K, Lucchesi M, Heijman T, van Benthem BH, van Bergen JE, Morre SA, Herbergs J, Kok G, Steenbakkers M, Hogewoning AA, de Vries HJ, Hoebe CJ. Design of the FemCu — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Detection of Chlamydia after treatment. Detection of anorectal and genital CT by NAAT 0-12 weeks after regular treatment
Secondary Culture of Chlamydia after treatment Detection of viable CT 0-12 weeks after regular treatment
Secondary Viability PCR of Chlamydia after treatment Detection of viable CT 0-12 weeks after regular treatment
Secondary CT concentration after treatment CT-DNA concentration 0-12 weeks after regular treatment
See also
  Status Clinical Trial Phase
Completed NCT04269434 - GonoScreen: Efficacy of Screening STIs in MSM N/A
Active, not recruiting NCT04139629 - Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI N/A
Completed NCT03107377 - Phase 2B/3 Double-blinded Placebo-controlled Phase 2/Phase 3
Completed NCT03098329 - Check it: A New Approach to Controlling Chlamydia Transmission in Young People N/A
Recruiting NCT03862495 - Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT N/A
Completed NCT05307991 - Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Terminated NCT02083276 - Mecillinam for Treatment of Genital Chlamydia Infection Phase 2
Active, not recruiting NCT06131749 - Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
Completed NCT03568695 - Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction (PCR) After Pooling Pharyngeal, Anorectal and Urinary Samples N/A
Completed NCT01448876 - Incubation Time and Test of Cure of Chlamydia Trachomatis N/A
Not yet recruiting NCT06369220 - A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections N/A
Not yet recruiting NCT06395675 - Clinical Evaluation of the ID NOW™ CT/NG Test N/A
Completed NCT03970850 - NeuMoDx PrEDiCTiNG Study Evaluation Plan N/A
Completed NCT01631201 - Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women Phase 2
Completed NCT05216744 - Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Phase 2
Recruiting NCT05581160 - Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST) N/A
Not yet recruiting NCT03532464 - Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Phase 4
Not yet recruiting NCT06234943 - Pharmacy-based Testing and Treatment for Gonorrhea and Chlamydia N/A
Active, not recruiting NCT04050540 - Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Phase 4
Completed NCT04955717 - Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences N/A

External Links